Genotyping HLA‐B*5801 for Allopurinol‐Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method

ObjectivesA new method of HLA-B*5801 genotyping was compared with sequence-based typing (SBT) to find an accurate and prompt method in genotyping HLA-B*5801. MethodsTwo groups of patients from allopurinol-induced cutaneous adverse reactions (SCARs) and allopurinol-tolerant were both genotyped with PG5801 kit and SBT method. The genotyping results of HLA-B*5801 were compared between the two groups. ResultsThe PG5801 detection kit results were 100% (79/79) in agreement with the SBT genotyping results for identifying the HLA-B*5801 (+) patients. No false-positive or false-negative errors were found. The sensitivity, specificity, rate of adherence, positive predictive value (PPV) and negative predictive value (NPV) were 100%. ConclusionThe potential fast screening method is an ideal tool to rule out the high-risk allopurinol-induced SCARs patients.